LEADER 02035nam  2200385z- 450 
001 9910261139803321
005 20231214133025.0
035   $a(CKB)4100000002484694
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/48184
035   $a(EXLCZ)994100000002484694
100   $a20202102d2017      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFunction of Renal Sympathetic Nerves
210   $cFrontiers Media SA$d2017
215   $a1 electronic resource (96 p.)
225 1 $aFrontiers Research Topics
311   $a2-88945-295-6 
330   $aSympathetic overactivity is associated with the development of hypertension. Renal denervation (RDN) prevents or delays hypertension in a variety of animal models, which laid the groundwork for the introduction of RDN as a clinical therapy in humans. In 2007, a novel, minimally invasive RDN ablation catheter was first trialled in hypertensive patients, with a 93% success rate of lowering blood pressure for at least three years post-RDN. However, a large scale, sham-controlled clinical trial (Symplicity HTN -3) failed to show reductions in BP greater than sham. The aim of this research topic was to evaluate the efficacy and safety of RDN, to explore the contribution of both afferent and efferent renal nerve activity to hypertension and non-hypertension disorders, and to stimulate future research to better understand the function of the renal nerves and the effects of RDN by highlighting gaps in knowledge.
610   $aatherosclerosis
610   $aheart failure
610   $arenal denervation
610   $arenal sympathetic nerves
610   $akidney disease
610   $ahypertension
700   $aYutang Wang$4auth$01331584
702   $aKate M. Denton$4auth
702   $aKyungjoon Lim$4auth
906   $aBOOK
912   $a9910261139803321
996   $aFunction of Renal Sympathetic Nerves$93040457
997   $aUNINA